Clinical Trial Update: Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating erlotinib for chemoprevention in patients with Primary Sclerosing Cholangitis (PSC) who have trisomy 7; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Sclerosing Cholangitis

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Mayo Clinic | Conditions: Primary Sclerosing Cholangitis, Trisomy 7 | Phase 1 | Status: COMPLETED